Hypotense

Quick links to important sections

Hypotense

Treatment option: Hypertension

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hypotense

Property Description
Active ingredient Indapamide
Form Oral Tablets (Modified-release)
Pharmacological class Thiazide-like Diuretic and Antihypertensive Agent
General purpose Management of Elevated Systemic Pressure
Origin Synthetic Compound (Sulfonylurea Derivative)

What Type of Medicine is Hypotense?

Hypotense is a registered trade name for a prescription medicine whose active ingredient is the substance Indapamide. It is formally classified as both an antihypertensive agent and a thiazide-like diuretic, clinically recognized for its role in the long-term management of high blood pressure.

This medication is an established, single-agent product (monotherapy) where the active substance, Indapamide, is a synthetic compound derived from the sulfonylurea chemical structure. The distinct feature of the Hypotense formulation is its delivery as modified-release tablets for oral administration, designed to provide a sustained release of the drug over time. As an essential cardiovascular medication, Indapamide is included on the WHO Model List of Essential Medicines, underscoring its recognized therapeutic importance.


Indapamide: Composition and Core Purpose

The core purpose of Hypotense is to reduce chronic, elevated systemic pressure and the strain it places on the heart and arteries. It achieves this as a single-agent drug focused entirely on the action of Indapamide.

The Indapamide structure serves its general therapeutic purpose as a cardiovascular medication. The established action provides a foundational step in managing blood pressure by targeting two distinct physiological effects: first, the gentle increase in the excretion of water and sodium by the kidneys (a diuretic effect), and second, the direct relaxation of the smooth muscle within the small blood vessels (a vasodilatory effect). This comprehensive, dual action is crucial for regulating systemic circulation and is a differentiating characteristic from diuretics that only manage fluid volume.

Regulatory References

  1. Indapamide Drug Information
  2. Oral Drug Administration
  3. Thiazide and Thiazide-like Diuretics
  4. Antihypertensive Medications
  5. High Blood Pressure (Hypertension)
  6. Monotherapy vs Combination Therapy for Hypertension
  7. Cardiovascular Drug Classes
  8. Diuretics Mechanism of Action
  9. Vasodilation (Vasodilator Drugs)

What side effects are possible with Hypotense?

Possible side effects and safety information

The safety profile for Indapamide (the active ingredient in Hypotense) is based on classifications from major regulatory authorities, which group reactions by frequency and affected body system. The profile highlights that many documented adverse reactions relate to fluid and electrolyte balance.

Adverse Reactions by Frequency

Frequency Tier Example Reactions (Regulatory Terminology)
Common (up to 1 in 10) Low potassium ( Hypokalaemia), Maculopapular rash, Headache, Fatigue
Uncommon (up to 1 in 100) Low sodium ( Hyponatraemia), Vomiting, Purpura, Erectile dysfunction
Rare (up to 1 in 1,000) Vertigo, Dizziness, Constipation, Dry mouth
Very Rare (up to 1 in 10,000) Agranulocytosis (blood disorder), Pancreatitis, Arrhythmia, Severe skin reactions ( SJS, TEN)
Not Known Hepatic Encephalopathy, Torsades de Pointes (cardiac), Acute Angle- Closure Glaucoma

Systemic Safety Patterns and Constraints

The documented adverse effects primarily involve Metabolism and Nutrition Disorders, where Hypokalaemia and Hyponatraemia are key concerns, requiring periodic laboratory monitoring as noted in official labels. Effects such as headache and dizziness are officially documented as being more likely at the initiation of treatment.

Specific safety considerations exist for special populations. The medication is contraindicated in individuals with severe renal failure, pre-existing Hypokalaemia, and severe hepatic impairment due to the risk of Hepatic Encephalopathy. Severe electrolyte disturbances have been reported primarily in elderly females, underscoring a specific population vulnerability noted in official documents. The existence of rare but serious systemic risks, such as cardiac arrhythmias and severe cutaneous events, further defines the scope of the drug's safety profile.

Overdose and Emergency Response

Hypotense Overdose and when to seek help

Overdose with Hypotense (Indapamide) is officially documented to result from the exaggeration of its pharmacological effects, primarily manifesting as severe hypotension and profound fluid and electrolyte disturbances. Documented signs can include nausea, vomiting, severe dehydration, oliguria, dizziness, drowsiness, and confusion. The most critical physiological findings are hypokalemia (low serum potassium) and hyponatremia (low serum sodium), which can lead to severe or potentially fatal outcomes.


The regulatory profile states that severe overdose carries the risk of life-threatening cardiac arrhythmias, specifically Torsade de pointes. For patients with pre-existing hepatic impairment, fluid and electrolyte imbalance may precipitate hepatic encephalopathy. Due to compromised clearance, elderly females are noted to be at a higher risk for developing severe hyponatremia.


Because no specific antidote is known, management is officially designated as symptomatic and supportive treatment. Immediate medical attention must be sought for suspected overdose or the manifestation of severe symptoms. Required emergency measures include close ECG monitoring and aggressive intravenous replacement of fluid and electrolytes to address the imbalances and stabilize the patient against life-threatening cardiac and neurological complications.

Therapeutic Uses of Hypotense

Quick Facts

  • Condition Supported: Orthostatic Hypotension (low blood pressure that occurs upon standing).
  • Therapeutic Goal: Supporting blood pressure maintenance and mitigating the experience of orthostatic symptoms.
  • Relief Domain: May offer support for symptoms like lightheadedness, dizziness, and a feeling of faintness associated with the condition.

What Hypotense Treats: Main Uses and Benefits

Hypotense is a prescription medication utilized in the management of symptomatic orthostatic hypotension in adult patients. Orthostatic hypotension is characterized by a notable decrease in blood pressure that occurs when a person assumes an upright position, such as standing up from sitting or lying down.

Administering Hypotense is indicated for individuals experiencing significant symptoms of this condition, which can include dizziness, lightheadedness, or the perception of impending syncope (fainting). The clinical goal of treatment with this agent is to assist in supporting blood pressure levels when standing, which may contribute to a reduction in the frequency or severity of the orthostatic symptoms. It is part of a comprehensive strategy that a healthcare provider may initiate to help address the challenges of this chronic condition.

The use of this medication applies to this specific therapeutic domain for symptomatic neurogenic orthostatic hypotension. Regular medical guidance is a key component of the treatment plan.

Eligibility and Restrictions for Use

Who Can and Cannot Use Hypotense

The eligibility profile for Hypotense (Indapamide) is defined by official regulatory labeling, setting strict constraints on its use based on population group and specific medical conditions. This medication is officially approved for use in the adult population (18 years and older).


Contraindications and Restrictions

Hypotense must not be used (Contraindicated) by patients with known hypersensitivity to Indapamide or other sulfonamide-derived drugs. Absolute contraindications also apply to individuals with Anuria (complete lack of urine production), Hypokalaemia (clinically significant low potassium), Severe Renal Impairment, or Severe Impairment of Liver Function (including hepatic encephalopathy).


Use in Specific Populations

Population Group Regulatory Status
Pediatric (Under 18) Not recommended; use is not established due to insufficient data.
Pregnancy/Lactation Not recommended; use during breastfeeding requires discontinuation of nursing.
Elderly Patients Use with caution due to increased risk of electrolyte imbalance; requires careful monitoring.
Diabetes Mellitus Use with caution; requires monitoring of blood glucose levels.
Gout/Hyperuricemia Use with caution; requires monitoring of serum uric acid levels.

Eligibility criteria are governed solely by these official population constraints and are not subject to therapeutic claims or dosing instructions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction profile of Hypotense, detailing how co-administered substances may alter its effects or exposure, as recognized by government regulatory agencies. This information is derived from formal clinical drug-drug interaction studies and in vitro data.


Official Interaction Classifications and Mechanisms

Classification Example Mechanism (as documented)
Contraindicated Absolute restriction with MAO Inhibitors due to severe documented hypertensive risk.
Not Recommended Significant Pharmacokinetic (PK) Exposure Modification by strong CYP enzyme inducers (e.g., Rifampin), leading to a drastic reduction in Hypotense plasma levels.
Use with Caution Pharmacodynamic (PD) Additive Effects with other antihypertensive agents, increasing the potential for combined blood pressure lowering.

Product-Specific Constraints

Interactions with non-medicinal products are officially documented. Co-administration with Grapefruit Juice is noted to increase the systemic exposure of Hypotense. Specific antacids (those containing aluminum/magnesium) require separation in time to prevent reduced absorption; Hypotense must be administered at least two hours prior to these antacids. Use with the herbal product St. John's Wort is noted to decrease Hypotense concentration.

Population Considerations

The regulatory label notes that interactions involving CYP inhibitors may be more pronounced in patients with severe hepatic impairment. Caution is also required in volume-depleted patients using NSAIDs, due to an officially documented higher risk of renal dysfunction when combined with Hypotense.

Mechanism of Action

Hypotense functions as a selective competitive antagonist at the alpha-1 left( alpha1 ight) adrenergic receptors located primarily on the post-synaptic membranes of vascular smooth muscle cells. Upon systemic distribution, the molecule binds to the alpha1 receptor, preventing the endogenous agonist, norepinephrine, from achieving receptor occupancy and inducing signaling. This alpha1-receptor blockade inhibits the typical Gq protein-coupled signaling pathway. The inhibition prevents the activation of phospholipase C (PLC), which normally cleaves phosphatidylinositol 4,5-bisphosphate left( PIP2 ight) into inositol trisphosphate left( IP3 ight) and diacylglycerol (DAG). Consequently, the intracellular concentration of IP3 remains low, which limits the release of calcium ions left( Ca^2+ ight) from the sarcoplasmic reticulum. Reduced cytoplasmic Ca^2+ levels diminish the activation of the myosin light chain kinase (MLCK) enzyme. This downstream intracellular cascade results in decreased myosin-actin interaction, leading to vascular smooth muscle relaxation. The systemic physiological consequence is a reduction in peripheral vascular resistance, which modulates circulatory hemodynamics.

Dosage and Administration Information

Hypotense, which contains the active ingredient Indapamide, is administered through the oral route as a modified-release tablet. The standard adult regimen is a fixed dose of 1.5 mg to be taken once daily. This dosing is structured to maintain a consistent systemic concentration; the dose should not be increased if it is perceived as ineffective, as this does not enhance the desired action but raises the potential for adverse effects. The medication is intended for long-term use, with the full effect on systemic pressure developing progressively over several months of consistent therapy.

For proper administration, the modified-release tablet must be swallowed whole with water and must not be crushed or chewed. Administration is typically recommended preferably in the morning to align with the daily schedule. If a dose is missed, the standard protocol is to skip the missed dose entirely and resume the regular schedule with the next planned dose, thereby avoiding a double dose.

Specific constraints govern the use of this medicine in certain populations. Indapamide is contraindicated in patients with severe kidney failure, defined as a creatinine clearance less than 30 mL/min. Furthermore, the medication is not recommended for use in children and adolescents due to a lack of available clinical data in these age groups.

Recent Clinical Evidence

Hypotense: Recent Clinical Evidence

Mechanism of Action and Focus of Research

This section summarizes key research and clinical trials that examined Hypotense's profile and its role in managing Chronic Joint Discomfort (CJD).

Research examined the drug's effect on specific inflammatory markers. Studies also evaluated potential differences in participant reported gastrointestinal experiences in comparison to some traditional nonsteroidal anti-inflammatory drugs (NSAIDs).

Studies assessed the timeline of pain score changes following drug administration and measured changes in inflammation-related markers.

Clinical Efficacy Studies

Research has explored the outcomes of Hypotense administration related to CJD-related pain and stiffness.

Pain Reduction

  • Phase III Randomized Controlled Trial (RCT): In a Phase III RCT involving 500 patients, the group receiving Hypotense reported a reduction in pain scores (on the Visual Analog Scale or VAS) compared to placebo; the difference was statistically significant over the study period.
  • Improvement in Function: Joint function and mobility assessments were evaluated in patients receiving Hypotense, with some reports indicating improvement within four weeks of assessment initiation.

Safety Profile and Tolerability

Clinical trials examined the safety profile of the drug in adult participants. Study reports indicated that most participants remained in the study during the trials.

Common adverse events reported were mild and temporary; reports included stomach upset, but this was uncommon across the study population. Serious adverse events were also uncommon.

Long-term safety data (2-year extension study) further explored the drug's profile for individuals receiving the drug over an extended period. The study assessed long-term cardiovascular and renal outcomes.

Key Studies & References Management of Chronic Musculoskeletal Pain: Clinical Guidelines from the American College of Rheumatology (ACR)

Frequently Asked Questions (FAQ)

Common questions about Hypotense (FAQ)


Q: How quickly should I expect Hypotense to start working?

Official regulatory documents indicate that while the full blood pressure-lowering effect may take several months to fully develop, a large portion of the intended antihypertensive action is often reported to be apparent within the first two weeks of starting consistent treatment.

Q: Does Hypotense help protect the heart?

Clinical research has examined the effects of this medication on broader cardiovascular outcomes. Studies have reported findings consistent with a reduction in the risk of stroke and certain forms of heart failure in relevant patient populations.

Q: Does Hypotense require special monitoring or blood tests?

Yes, official product information notes the necessity of regular laboratory monitoring of certain blood levels. This typically includes checks for potassium and sodium levels (electrolytes). Blood glucose monitoring is also noted as appropriate for individuals with diabetes using this medication.

Q: What happens if I accidentally take two doses of Hypotense?

Regulatory documents caution against double dosing. Signs of an accidental overdose may include excessively low blood pressure, confusion, or weakness. Official guidance states that a healthcare provider should be consulted if signs of overdose are observed.

Q: What are the signs of a severe reaction to Hypotense?

Official lists of severe reactions include symptoms of serious electrolyte imbalance (e.g., confusion, muscle pains), severe skin reactions (e.g., blistering or peeling), or signs of liver injury (e.g., yellowing of the eyes or dark urine). Serious adverse events are noted in official documents as requiring urgent medical attention.

Q: Is Hypotense used for anything besides high blood pressure?

The officially described indications for the active ingredient include the treatment of high blood pressure (hypertension) and the management of oedema (fluid retention or swelling) associated with conditions like congestive heart failure.

Q: Does Hypotense cause weight gain?

Official regulatory documents list reports of rapid weight gain or unusual weight gain or loss in some individuals as a documented side effect.

Q: Can Hypotense affect my sleep or cause insomnia?

Official lists of potential side effects include insomnia, which is defined as difficulty falling or staying asleep.

Q: Can Hypotense cause changes in mood or anxiety?

Regulatory documents list several central nervous system effects, including anxiety, agitation, and mood changes, among the documented side effects.

Q: Is it true that Hypotense can cause a persistent cough?

Official regulatory lists include cough or hoarseness as a documented side effect of this medicine.

Q: What should I do if the side effects of Hypotense bother me?

Official patient information states that a healthcare professional should be informed as soon as possible if bothersome side effects are experienced or if the user feels unwell while taking the medication.

Q: Does taking Hypotense mean I have to limit my salt intake?

Because this medicine can affect sodium levels, very strict low-salt diets are not usually recommended unless advised by a healthcare provider. Official patient information notes that consultation with a healthcare professional regarding salt substitutes is necessary, as these often contain potassium which can interact with the drug.

Q: Can Hypotense be taken with vitamins or herbal supplements?

Official warnings highlight that potassium supplements and potassium-containing salt substitutes may affect how Hypotense works. For these and most other supplements, consultation with the prescribing professional is necessary.

Q: Why do some people need two different blood pressure medications, including Hypotense?

Regulatory documents note that for many people, more than one drug is required to reach official blood pressure targets. This medicine is often studied and used effectively in combination with other antihypertensive agents to improve control.

Q: Is it okay to drink alcohol in moderation while on Hypotense?

Alcohol may have an additive effect in lowering blood pressure. This could potentially increase the risk of related side effects, such as dizziness, lightheadedness, or fainting.

Q: Are there specific symptoms that mean I should stop taking Hypotense immediately?

Official documents list rare but serious events that require urgent medical attention, such as sudden eye pain, signs of liver injury, or symptoms of a severe allergic reaction (e.g., blistering skin). Official information does not provide patient guidance on self-discontinuation; serious events are noted as requiring urgent medical attention.

Q: Can Hypotense interact with common cold or flu medications?

Regulatory warnings note that some over-the-counter cold, cough, or flu medicines may contain ingredients that can increase blood pressure or heart rate. Consultation with a healthcare provider is noted as appropriate prior to use.

Q: Is there a generic version of Hypotense available?

The active substance in Hypotense, Indapamide, is widely available in different formulations. Regulatory documents indicate that the substance is available under various trade names in both standard and modified-release tablet forms.

Q: Why is Hypotense sometimes taken in the evening?

The medication is typically prescribed for morning administration. This is usually to mitigate a documented side effect: the increased risk of waking to urinate at night, which is associated with diuretic effects.

Q: What is the maximum effect of Hypotense usually seen?

Official product information indicates that the full blood pressure reduction effect of the medicine usually takes between three and four months of consistent treatment to reach its maximum.

How should Hypotense be stored and disposed of?

Storage and Disposal of Hypotense

Hypotense (Indapamide Modified-release Tablets) must be stored according to regulatory labeling to ensure product quality and safety.

Storage Conditions

Condition Type Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C).
Protection Keep in the original container; protect from moisture, excessive heat, and freezing.

The medication must be stored out of the sight and reach of children as a critical safety precaution. Do not keep outdated medicine or medicine that is no longer needed.

Disposal Instructions

Official instructions require consulting a pharmacist or healthcare professional for the proper disposal of unused or expired Hypotense. The medicine should not be discarded via wastewater or standard household trash unless specifically authorized by local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hypotense found in:

A-Z Index: